Get started
Author

Manoj A. Jivani

Observed names: M. Jivani, M.A. Jivani, Manoj A Jivani, Manoj Jivani, Manoj jivani
OpenAlex ID: A5035978871
An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma
2018 · Toni K. Choueiri, M. Dror Michaelson, et al. · The Oncologist · 29
PDF
ENGINE: A Phase III Randomized Placebo Controlled Study of Enzastaurin/R-CHOP as Frontline Therapy in High-Risk Diffuse Large B-Cell Lymphoma Patients with the Genomic Biomarker DGM1
2020 · Grzegorz S Nowakowski, Jun Zhu, et al. · Future Oncology · 22
A phase 2 trial of TRC105 with bevacizumab for bevacizumab refractory glioblastoma.
2016 · Manmeet Singh Ahluwalia, Lisa R. Rogers, et al. · Journal of Clinical Oncology · 11
A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma.
2015 · Toni K. Choueiri, M Dror Michaelson, et al. · Journal of Clinical Oncology · 11
A phase 1b dose-escalation study of TRC105 (endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC)
2016 · T. Choueiri, M.D. Michaelson, et al. · Annals of Oncology · 5
A phase 1b dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC).
2014 · Toni K. Choueiri, Edwin M. Posadas, et al. · Journal of Clinical Oncology · 5
TRAXAR study: a randomized phase 2 trial of axitinib and TRC105 versus axitinib alone in patients with advanced or metastatic renal cell carcinoma (mRCC)
2016 · T. Choueiri, N. Agarwal, et al. · Annals of Oncology · 3
A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with capecitabine for advanced solid tumors (including patients with progressive or recurrent HER2-negative metastatic breast cancer).
2013 · Ellis Glenn Levine, Andres Forero, et al. · Journal of Clinical Oncology · 3
Protein Kinase C Isoform (PKC) Peptide Activator/Inhibitors Exert Cardioprotective Effects in Polymorphonuclear Leukocyte (PMN)-induced Ischemia/Reperfusion (I/R) Injury
2006 · Lindon H. Young, Aisha Phillipson, et al. · Springer eBooks · 3
Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1
2019 · Jun Zhu, Grzegorz Nowakowski, et al. · Blood · 1
DGM1 may serve as a novel genetic biomarker of response to enzastaurin in glioblastoma.
2019 · Nicholas A. Butowski, Ronald L. Shazer, et al. · Journal of Clinical Oncology · 1
Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy.
2017 · Yingmiao Liu, Zhenhua Yuan, et al. · Journal of Clinical Oncology · 1
Rbtt-04. Dgm1 May Serve as a Novel Genetic Biomarker of Response to Enzastaurin in Glioblastoma
2019 · Nicholas Butowski, Lei Zhang, et al. · Neuro-Oncology
PDF
Phase Iii Randomized Study of Enzastaurin/r‐chop Vs Placebo/r‐chop in Frontline High Risk Diffuse Large B Cell Lymphoma Patients With Genomic Biomarker Dgm1 (engine Study)
2019 · J. Zhu, Y. Song, et al. · Hematological Oncology
PDF
ENGINE: Phase III randomized study of enzastaurin/R-CHOP versus placebo/R-CHOP in frontline high-risk diffuse large B-cell lymphoma patients with novel genomic biomarker DGM1.
2019 · Stephen Smith, Jun Zhu, et al. · Journal of Clinical Oncology
Works count: 15
Citation count: 95
H-index: 5
I10-index: 4
Year
Topic
Type